Loading patent…
AssigneeHolosmedic
InventorsKi Cheong PARK, Jae Ho CHEONG, Seok Mo KIM, Yeo Jin YUN, Byeong Mo KIM
Estimating the term…
The present invention relates to a novel compound and a pharmaceutical composition for enhancing anticancer activity, which includes the same, and more particularly, to a pharmaceutical composition, which includes a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, thereby enhancing anticancer activity of an anticancer agent or radiation, and inducing proliferation inhibition and death of cancer cells, resulting in effectively treating cancer:
A compound represented by Formula 1 or a pharmaceutically acceptable salt thereof:
(canceled)
-15. (canceled)
The pharmaceutical composition of claim 15, wherein the anticancer agent is at least one selected from the group consisting of nitrogen mustard, imatinib, oxaliplatin, rituximab, erlotinib, neratinib, lapatinib, gefitinib, vandetanib, nilotinib, semasanib, bosutinib, axitinib, macitinib, cediranib, restaurtinib, trastuzumab, gefitinib, bortezomib, sunitinib, pazopanib, toceranib, nintedanib, regorafenib, semaksanib, tibozanib, ponatinib, cabozantinib, carboplatin, sorafenib, renbatinib, bevacizumab, cisplatin, cetuximab, viscumalbum, asparaginase, tretinoin, hydroxycarbamide, dasatinib, estramustine, gemtuzumab ozogamycin, ibritumomab tucetan, heptaplastin, methylaminolevulinic acid, amsacriine, alemtuzumab, procarbazine, alprostadil, holmium nitrate, chitosa, gemcitabine, doxyfluridine, pemetrexed, tegapur, capecitabine, gimeracil, oteracil, azacitidine, methotrexate, uracil, cytarabine, 5-fluorouracil, fludagabine, enocitabine, flutamide, kefecitabine, decitabine, mercaptopurine, thioguanine, cladribine, carmofur, raltitrexed, docetaxel, paclitaxel, irinotecan, velotecan, topotecan, binorelbine, etoposide, vincristine, vinblastine, teniposide, doxorubicin, idarubicin, epirubicin, mitoxantrone, mitomycin, bleromycin, daunorubicin, dactinomycin, pararubicin, aclarubicin, pepromycin, temsirolimus, temozolomide, busulfan, ifosfamide, cyclophosphmide, melparan, altretm in, dacarbazine, thiotepa, bimustine, chlorambucil, mitoractol, leucovorin, tretonin, exnestane, am inoglutesim ide, anagrelide, olaparib, navelbine, padrazol, tamoxifen, toremifen, testolactone, anastrozole, letrozole, borozole, bicalutamide, lomustine, vorinostat, entinostat and carmustine.
The pharmaceutical composition of claim 15, wherein the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof and the anticancer agent are contained at a molar concentration ratio of 1:0.001 to 1:1000.
-20. (canceled)
-29. (canceled)
Dependencies are inferred from the claim text.